Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis.

@article{Dasarathy2015DoubleblindRP,
  title={Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis.},
  author={Srinivasan Dasarathy and Jaividhya Dasarathy and Amer Khiyami and Lisa M. Yerian and Carol Hawkins and Ruth Sargent and Arthur Joseph McCullough},
  journal={Journal of clinical gastroenterology},
  year={2015},
  volume={49 2},
  pages={137-44}
}
BACKGROUND Nonalcoholic steatohepatitis (NASH) is common and severe in patients with diabetes mellitus. Although, there are no effective treatments for NASH in diabetic patients, preliminary reports suggest that polyunsaturated fatty acids (PUFA) may be beneficial in these patients. AIM A prospective, randomized, double-blind placebo-controlled study (NCT 00323414) was performed in NASH patients with diabetes. Clinicaltrials.gov (NCT 00323414). SUBJECTS AND METHODS A total of 37 patients… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 42 extracted citations

Current treatment for non-alcoholic fatty liver disease.

Revista de gastroenterologia de Mexico • 2018
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 59 references

Similar Papers

Loading similar papers…